Hepatosplenic T-cell lymphoma, immunosuppressive agents and biologicals: What are the risks?

K. Subramaniam; D. Yeung; F. Grimpen; J. Joseph; K. Fay; M. Buckland; D. Talaulikar; J. Elijah; A. C. Clarke; P. Pavli; J. Moore

doi:10.1111/imj.12363

Hepatosplenic T-cell lymphoma, immunosuppressive agents and biologicals: What are the risks?

K. Subramaniam^*, D. Yeung, F. Grimpen, J. Joseph, K. Fay, M. Buckland, D. Talaulikar, J. Elijah, A. C. Clarke, P. Pavli, J. Moore

^*Corresponding author for this work

Research output: Contribution to journal › Article › peer-review

23 Citations (Scopus)

Abstract

We present three cases of the rare hepatosplenic T-cell lymphoma (HSTCL); two patients suffering from Crohn disease who developed HSTCL on azathioprine without exposure to biologicals, and a third patient who had psoriasis treated using etanercept, cyclosporine and methotrexate. The evidence for an association between HSTCL and immunosuppressive drugs and biologicals is reviewed. We argue for improved pharmacovigilance processes to help determine the benefit to risk ratios for the use of these and other new agents.

Original language	English
Pages (from-to)	287-290
Number of pages	4
Journal	Internal Medicine Journal
Volume	44
Issue number	3
DOIs	https://doi.org/10.1111/imj.12363
Publication status	Published - Mar 2014
Externally published	Yes

Access to Document

10.1111/imj.12363

Cite this

@article{74bf25a815ca483890701716ca16e5f8,

title = "Hepatosplenic T-cell lymphoma, immunosuppressive agents and biologicals: What are the risks?",

abstract = "We present three cases of the rare hepatosplenic T-cell lymphoma (HSTCL); two patients suffering from Crohn disease who developed HSTCL on azathioprine without exposure to biologicals, and a third patient who had psoriasis treated using etanercept, cyclosporine and methotrexate. The evidence for an association between HSTCL and immunosuppressive drugs and biologicals is reviewed. We argue for improved pharmacovigilance processes to help determine the benefit to risk ratios for the use of these and other new agents.",

keywords = "Biologicals, Hepatosplenic T-cell lymphoma, Immunosuppression, Inflammatory bowel disease, Psoriasis",

author = "K. Subramaniam and D. Yeung and F. Grimpen and J. Joseph and K. Fay and M. Buckland and D. Talaulikar and J. Elijah and Clarke, {A. C.} and P. Pavli and J. Moore",

year = "2014",

month = mar,

doi = "10.1111/imj.12363",

language = "English",

volume = "44",

pages = "287--290",

journal = "Internal Medicine Journal",

issn = "1444-0903",

publisher = "Wiley-Blackwell Publishing Ltd",

number = "3",

}

TY - JOUR

T1 - Hepatosplenic T-cell lymphoma, immunosuppressive agents and biologicals

T2 - What are the risks?

AU - Subramaniam, K.

AU - Yeung, D.

AU - Grimpen, F.

AU - Joseph, J.

AU - Fay, K.

AU - Buckland, M.

AU - Talaulikar, D.

AU - Elijah, J.

AU - Clarke, A. C.

AU - Pavli, P.

AU - Moore, J.

PY - 2014/3

Y1 - 2014/3

N2 - We present three cases of the rare hepatosplenic T-cell lymphoma (HSTCL); two patients suffering from Crohn disease who developed HSTCL on azathioprine without exposure to biologicals, and a third patient who had psoriasis treated using etanercept, cyclosporine and methotrexate. The evidence for an association between HSTCL and immunosuppressive drugs and biologicals is reviewed. We argue for improved pharmacovigilance processes to help determine the benefit to risk ratios for the use of these and other new agents.

AB - We present three cases of the rare hepatosplenic T-cell lymphoma (HSTCL); two patients suffering from Crohn disease who developed HSTCL on azathioprine without exposure to biologicals, and a third patient who had psoriasis treated using etanercept, cyclosporine and methotrexate. The evidence for an association between HSTCL and immunosuppressive drugs and biologicals is reviewed. We argue for improved pharmacovigilance processes to help determine the benefit to risk ratios for the use of these and other new agents.

KW - Biologicals

KW - Hepatosplenic T-cell lymphoma

KW - Immunosuppression

KW - Inflammatory bowel disease

KW - Psoriasis

UR - http://www.scopus.com/inward/record.url?scp=84896849512&partnerID=8YFLogxK

U2 - 10.1111/imj.12363

DO - 10.1111/imj.12363

M3 - Article

SN - 1444-0903

VL - 44

SP - 287

EP - 290

JO - Internal Medicine Journal

JF - Internal Medicine Journal

IS - 3

ER -

Hepatosplenic T-cell lymphoma, immunosuppressive agents and biologicals: What are the risks?

Abstract

Access to Document

Other files and links

Fingerprint

Cite this